Verastem Financials
| VSTM Stock | USD 5.82 0.02 0.34% |
Verastem Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.35 | 3.53 |
|
|
The essential information of the day-to-day investment outlook for Verastem includes many different criteria found on its balance sheet. An individual investor should research Verastem's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Verastem.
Net Income |
|
Verastem | Select Account or Indicator | Build AI portfolio with Verastem Stock |
Verastem Stock Summary
Verastem competes with Regenxbio, Absci Corp, MoonLake Immunotherapeuti, Kalvista Pharmaceuticals, and Prothena Plc. Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. Verastem operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 48 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US92337C2035 |
| Business Address | 117 Kendrick Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.verastem.com |
| Phone | 781 292 4200 |
| Currency | USD - US Dollar |
Verastem Key Financial Ratios
| Return On Equity | -28.89 | ||||
| Operating Margin | (3.62) % | ||||
| Price To Sales | 32.76 X | ||||
| Revenue | 10 M | ||||
| Gross Profit | 11.39 M |
Verastem Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 108.7M | 95.1M | 149.7M | 101.5M | 116.8M | 124.5M | |
| Other Current Liab | 15.6M | 15.0M | 18.3M | 26.0M | 29.8M | 31.3M | |
| Accounts Payable | 2.3M | 4.9M | 7.2M | 4.0M | 4.6M | 5.0M | |
| Cash | 21.3M | 74.9M | 77.9M | 88.8M | 102.1M | 53.6M | |
| Other Current Assets | 5.0M | 4.9M | 6.6M | 5.9M | 6.8M | 7.2M | |
| Total Liab | 21.1M | 47.7M | 92.3M | 130.4M | 150.0M | 157.5M | |
| Common Stock | 8K | 17K | 19K | 20K | 4.6K | 7.4K | |
| Net Debt | (18.1M) | (47.9M) | (36.4M) | (46.6M) | (41.9M) | (39.8M) | |
| Retained Earnings | (663.7M) | (737.5M) | (824.9M) | (955.5M) | (860.0M) | (817.0M) | |
| Other Assets | 36.1M | 9.0M | 410K | 299K | 343.9K | 326.7K | |
| Total Current Assets | 105.7M | 92.9M | 143.7M | 95.0M | 109.2M | 118.1M | |
| Net Tangible Assets | (12.8M) | 115.3M | 87.6M | 47.4M | 42.7M | 63.3M | |
| Long Term Debt | 249K | 24.5M | 40.1M | 40.7M | 46.8M | 30.3M | |
| Net Receivables | 516K | 31K | 42K | 200K | 180K | 171K | |
| Capital Surpluse | 531.9M | 707.7M | 751.2M | 784.9M | 902.6M | 481.7M | |
| Long Term Debt Total | 103.6M | 19.1M | 249K | 24.5M | 22.1M | 36.9M | |
| Net Invested Capital | 87.8M | 72.2M | 97.5M | 11.8M | 10.6M | 10.1M |
Verastem Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Operating Income | (61.4M) | (72.9M) | (92.1M) | (115.0M) | (103.5M) | (98.3M) | |
| Research Development | 39.3M | 50.6M | 61.4M | 81.3M | 93.5M | 98.2M | |
| Ebitda | (61.2M) | (71.6M) | (83.2M) | (125.9M) | (113.3M) | (107.6M) | |
| Income Before Tax | (71.2M) | (73.8M) | (87.4M) | (130.5M) | (117.4M) | (111.5M) | |
| Net Income | (71.2M) | (73.8M) | (87.4M) | (130.6M) | (117.6M) | (111.7M) | |
| Interest Expense | 10.0M | 2.1M | 4.1M | 4.6M | 5.2M | 5.0M | |
| Ebit | (61.2M) | (71.7M) | (83.2M) | (125.9M) | (113.3M) | (107.6M) | |
| Total Revenue | 88.5M | 2.1M | 2.6M | 10M | 11.5M | 12.5M | |
| Gross Profit | 2.1M | 2.6M | (62K) | 10M | 11.5M | 9.2M | |
| Cost Of Revenue | 206K | 118K | 62K | 26K | 29.9K | 28.4K | |
| Income Tax Expense | 9.9M | 36K | (87.4M) | 185K | 166.5K | 174.8K | |
| Net Interest Income | (9.8M) | (922K) | 1.4M | (413K) | (475.0K) | (498.7K) | |
| Interest Income | 181K | 1.2M | 5.1M | 4.1M | 4.8M | 5.0M |
Verastem Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Free Cash Flow | (53.7M) | (63.7M) | (86.5M) | (104.8M) | (94.3M) | (89.6M) | |
| Other Non Cash Items | 9.3M | 228K | (4.1M) | 14.8M | 17.0M | 17.8M | |
| Capital Expenditures | 33K | 196K | 0.0 | 28K | 32.2K | 30.6K | |
| Net Income | (71.2M) | (73.8M) | (87.4M) | (130.6M) | (117.6M) | (111.7M) | |
| End Period Cash Flow | 21.5M | 75.8M | 79.1M | 89.1M | 102.4M | 56.5M | |
| Change In Cash | (46.5M) | 54.3M | 3.3M | 10.0M | 9.0M | 4.9M | |
| Depreciation | 72K | (36K) | 62K | 26K | 29.9K | 28.4K | |
| Investments | 283K | 66.2M | (43.9M) | 60.0M | 69.0M | 72.4M | |
| Change To Netincome | 8.5M | 10.9M | 7.7M | 6.0M | 5.4M | 6.6M | |
| Net Borrowings | 1.1M | 24.1M | 14.6M | (150K) | (135K) | (128.3K) | |
| Change Receivables | (2.2M) | 2.3M | (277K) | 485K | 557.8K | 585.6K |
Verastem Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Verastem's current stock value. Our valuation model uses many indicators to compare Verastem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Verastem competition to find correlations between indicators driving Verastem's intrinsic value. More Info.Verastem is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Verastem's Return On Equity is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Verastem by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Most indicators from Verastem's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Verastem current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.At this time, Verastem's Tax Provision is very stable compared to the past year. As of the 15th of February 2026, Enterprise Value is likely to grow to about 320.8 M, while Selling General Administrative is likely to drop about 36.6 M.
Verastem fundamental ratios Correlations
Click cells to compare fundamentals
Verastem Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Verastem fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 108.7M | 95.1M | 149.7M | 101.5M | 116.8M | 124.5M | |
| Other Current Liab | 15.6M | 15.0M | 18.3M | 26.0M | 29.8M | 31.3M | |
| Accounts Payable | 2.3M | 4.9M | 7.2M | 4.0M | 4.6M | 5.0M | |
| Cash | 21.3M | 74.9M | 77.9M | 88.8M | 102.1M | 53.6M | |
| Other Current Assets | 5.0M | 4.9M | 6.6M | 5.9M | 6.8M | 7.2M | |
| Total Liab | 21.1M | 47.7M | 92.3M | 130.4M | 150.0M | 157.5M | |
| Common Stock | 8K | 17K | 19K | 20K | 4.6K | 7.4K | |
| Net Debt | (18.1M) | (47.9M) | (36.4M) | (46.6M) | (41.9M) | (39.8M) | |
| Retained Earnings | (663.7M) | (737.5M) | (824.9M) | (955.5M) | (860.0M) | (817.0M) | |
| Other Assets | 36.1M | 9.0M | 410K | 299K | 343.9K | 326.7K | |
| Total Current Assets | 105.7M | 92.9M | 143.7M | 95.0M | 109.2M | 118.1M | |
| Net Tangible Assets | (12.8M) | 115.3M | 87.6M | 47.4M | 42.7M | 63.3M | |
| Long Term Debt | 249K | 24.5M | 40.1M | 40.7M | 46.8M | 30.3M | |
| Net Receivables | 516K | 31K | 42K | 200K | 180K | 171K | |
| Capital Surpluse | 531.9M | 707.7M | 751.2M | 784.9M | 902.6M | 481.7M | |
| Long Term Debt Total | 103.6M | 19.1M | 249K | 24.5M | 22.1M | 36.9M | |
| Net Invested Capital | 87.8M | 72.2M | 97.5M | 11.8M | 10.6M | 10.1M |
Today, most investors in Verastem Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Verastem's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Verastem growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Verastem February 15, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Verastem help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Verastem. We use our internally-developed statistical techniques to arrive at the intrinsic value of Verastem based on widely used predictive technical indicators. In general, we focus on analyzing Verastem Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Verastem's daily price indicators and compare them against related drivers.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 29.76 | |||
| Value At Risk | (7.51) | |||
| Potential Upside | 6.21 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verastem. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Verastem Stock, please use our How to Invest in Verastem guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Verastem diversify its offerings? Factors like these will boost the valuation of Verastem. If investors know Verastem will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Verastem data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.28) | Revenue Per Share | Quarterly Revenue Growth (0.79) | Return On Assets | Return On Equity |
The market value of Verastem is measured differently than its book value, which is the value of Verastem that is recorded on the company's balance sheet. Investors also form their own opinion of Verastem's value that differs from its market value or its book value, called intrinsic value, which is Verastem's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Verastem's market value can be influenced by many factors that don't directly affect Verastem's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verastem's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verastem is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Verastem's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.